Making the Case for Accelerated Withdrawal of Aducanumab.

Area of Science:

• Neurology
• Pharmacology
• Public Health Policy

Background:

• The U.S. Food and Drug Administration (FDA) controversially approved aducanumab (Aduhelm) in June 2021.
• Aducanumab is a monoclonal antibody treatment for Alzheimer's disease.
• Concerns exist regarding its clinical efficacy, safety profile, and high cost.

Purpose of the Study:

• To convene experts and stakeholders to discuss the withdrawal of aducanumab's FDA approval.
• To evaluate the evidence supporting and opposing the continued approval of aducanumab.
• To formulate a collective recommendation regarding aducanumab's regulatory status.

Main Methods:

• An international meeting was held on December 15, 2021.
• Participants included clinicians, scientists, dementia patients, and public health advocates.
• Attendees debated arguments for and against withdrawal and voted on a recommendation.

Main Results:

• Unanimous vote to recommend the FDA withdraw approval for aducanumab.
• Support for the Right Care Alliance's Citizen Petition to revoke the drug's approval.
• Consensus on the inadequacy of evidence for aducanumab's clinical benefit.

Conclusions:

• The current evidence does not support the continued approval of aducanumab for Alzheimer's disease.
• Regulatory bodies should reconsider drug approval processes based on robust efficacy and safety data.
• Patient and public health perspectives are crucial in drug evaluation.